Ireland
--:--IST
Recruiting Observational

Predicting Weight Loss After Pharmacological or Surgical Treatment in Patients With Obesity

NCT07402031 · tracked via the Priya Life Science Belgium tracker
Phase
Observational
Started
2026-05-05
Last updated
2026-05-14

Condition(s) studied

Obesity & Overweight

Investigational drug(s) / intervention(s)

Pharmacological or surgical treament of obesity

Pharmacological or surgical treament of obesity: Longitudinal follow-up of participants who initiate an anti-obesity medication or whose application for bariatric surgery was accepted. It will combine anthropometric, clinical, neuropsychological and biological measurements taken at various timepoints. Participants will be asked to complete a set of online questionnaires and data will be recorded anonymously. Biological samples will be collected at various time points.

Study summary

As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion criteria: * Age between 18 and 65 years * Obesity, with bariatric surgery indicated after a multidisciplinary evaluation in case of surgical treatment. * Good physical and mental health, enabling informed consent. * French speaker Exclusion criteria: * Legal protection * Pregnancy or breastfeeding * History of bariatric surgery (except gastric banding, provided it was removed more than five years ago). * Acute or progressive chronic disease * Alcohol consumption of more than 20 g/day * Inflammatory bowel disease; * Digestive autonomic diabetic neuropathy. * Consumption of dietary supplements (stanols, probiotics, prebiotics or omega-3). * Following a vegan or gluten-free diet or being lactose intolerant. * Fibre consumption \>30 g/day * Recent change in antidiabetic medication within the past 3 months.

Primary outcome measure(s)

  • Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters. — Throughout the entire study, aproximately during 5 years
    The percentage of excessive weight loss after treatment will be correlated with * Clinical parameters (Binge Eating Scale and modified Yale Food Addiction Scale 2.0) * Neuropsychological parameter (Barratt Impulsivness Scale and Trail Making Test) * Biological parameters

Trial sites (1)

FacilityCityRegionStatus
Cliniques Universitaires Saint-Luc Brussels Brussels Capital Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07402031 on ClinicalTrials.gov ↗ ← All trials in Belgium